OraSure Technologies, Inc.
OraSure Technologies, Inc. (Nasdaq: OSUR) develops, manufactures, markets and distributes diagnostic tests and sample management products for customers in healthcare, public health, research and commercial markets. Its rapid diagnostic tests address HIV, hepatitis C, syphilis, sickle cell disease and COVID-19, with… From the company’s description.
Over the twelve months to Jun 30, 2026, OraSure Technologies, Inc. reported revenue of $112.41M, down 18.9% from a year earlier, and a net loss of $49.13M. Its operating margin was −48.1%, and operations used $42.88M in cash. In fiscal 2025, it reported revenue of $115.02M, down 38.1% from fiscal 2024, and a net loss of $68.73M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OraSure Technologies, Inc. does
In the company’s own words
OraSure Technologies, Inc. (Nasdaq: OSUR) develops, manufactures, markets and distributes diagnostic tests and sample management products for customers in healthcare, public health, research and commercial markets. Its rapid diagnostic tests address HIV, hepatitis C, syphilis, sickle cell disease and COVID-19, with products sold to laboratories, hospitals, clinics, public health organizations, government agencies, distributors and consumers. Its sample management solutions collect, stabilize, transport and store biological specimens, including saliva, urine, blood and microbiome samples, for clinical testing, consumer genetics, pharmaceutical, biotechnology, academic research and animal health applications. OraSure operates as one business unit, with a single reporting hierarchy and multiple product lines spanning diagnostics and sample management. Key brands include OraQuick, InteliSwab, Oragene, ORAcollect, OMNIgene and Colli-Pee. The company acquired BioMedomics in November 2025, adding the SickleSCAN point-of-care test to its portfolio. For fiscal 2025, OraSure reported $49.8 million in OraQuick HIV product revenue and employed 500 full-time employees as of year-end. Its website is www.orasure.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- BETHLEHEM, PA
- Fiscal year end
- December
- CIK
- 1116463
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OraSure Technologies, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OraSure Technologies, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OraSure Technologies, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OraSure Technologies, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OraSure Technologies, Inc.'s last four quarterly filings that the numbers alone won't show?”